Photo: Boris Roessler / TASS
Tests of the combined use of AstraZeneca coronavirus vaccines as the first component and the Sputnik Light vaccine as the second showed the safety of such a combination. This is reported by the Russian Direct Investment Fund (RDIF), based on the interim results of phase II clinical trials to assess the safety of the combined use of vaccines.
“Preliminary data from the combined use of Sputnik Light and AstraZeneca vaccines confirm the correct use of different vaccines during revaccination. In the context of the emergence of new dangerous strains of coronavirus, it is this approach that can provide safe, effective and long-term protection,” said Kirill Dmitriev, CEO of RDIF.
The studies took place in Russia and Azerbaijan, and involved 100 volunteers in each country. The participants in the experiment were observed for 57 days after the first vaccination. “There were no serious adverse events associated with vaccination during follow-up,” the RDIF said in a press release.
Clinical trials of the combination of vaccines in Azerbaijan began in February 2021. In September 2021, RDIF reported that, according to the interim result, in 85% of study participants (data were based on the results of observations of 20 first volunteers), the number of neutralizing antibodies to the S protein of the SARS-CoV-2 virus on the 57th day of observation increased by four times or more.
The material is complemented